- $1.66bn
- $1.37bn
- $184.42m
Brief: Stoke Therapeutics Appoints Ian Smith As Chief Executive Officer
Brief: Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing
Brief: Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Biogen And Stoke Therapeutics Announce First Patient Dosed In Phase 3 Emperor Study Of Zorevunersen
Stoke Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview
Stoke Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview
Stoke Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Stoke Therapeutics Q1 Operating Income USD 111.24 Million
Stoke Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Stoke Therapeutics Appoints Director Ian F. Smith Interim Chief Executive Officer
Brief: Biogen And Stoke Therapeutics Enter Into Collaboration
Brief: Stoke Therapeutics Plans To Initiate Phase 3 Study Of Zorevunersen To Treat Dravet Syndrome On Alignment With Global Regulatory Agencies
U.S. STOCKS ON THE MOVE-Stoke Therapeutics, Foot Locker, Marvell
Stoke rises on FDA's 'breakthrough therapy' tag for epileptic disorder drug
Brief: Stoke Therapeutics Receives FDA Breakthrough Therapy Designation For Zorevunersen For The Treatment Of Dravet Syndrome
Stoke Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Stoke Therapeutics Inc - Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing
Brief: Skorpios Trust Reports 16.9% Stake In Stoke Therapeutics As Of Sept 19 Versus 23.4% As Of April 17- SEC Filing